NSJ Bioreagents
SKU:V9537-20UG
Recombinant CD43 Antibody, 20 ug
Recombinant CD43 Antibody, 20 ug
Couldn't load pickup availability
It recognizes a cell surface glycoprotein of 95/115/135kDa (depending upon the extent of glycosylation), identified as CD43. 70-90% of T-cell lymphomas and from 22-37% of B-cell lymphomas express CD43. No reactivity has been observed with reactive B-cells. So a B-lineage population that co-expresses CD43 is highly likely to be a malignant lymphoma, especially a low-grade lymphoma, rather than a reactive B-cell population. When CD43 antibody is used in combination with anti-CD20, effective immunophenotyping of the lymphomas in formalin-fixed tissues can be obtained. Co-staining of a lymphoid infiltrate with anti-CD20 and anti-CD43 argues against a reactive process and favors a diagnosis of lymphoma.
Specifications
| Catalog No | V9537-20UG |
|---|---|
| Family | Primary antibody |
| Qty | 20 ug |
| Formulation | 0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced), 0.05% sodium azide |
| Format | Purified |
| Clone | SPN/6562R |
| Host Animal | Rabbit |
| Clonality | Recombinant Rabbit Monoclonal |
| Isotype | Rabbit IgG, kappa |
| Species Reactivity | Human |
| Application | IHC-P |
| Application Details | Immunohistochemistry (FFPE): 1-2ug/ml |
| Application Note | Optimal dilution of the recombinant CD43 antibody should be determined by the researcher. |
| Localization | Cell surface |
| Immunogen | Recombinant full-length human protein was used as the immunogen for the recombinant CD43 antibody. |
| Purity | Protein A affinity |
| Storage | Aliquot the recombinant CD43 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles. |
| Limitation | This recombinant CD43 antibody is available for research use only. |
| Uniprot # | P16150 |
| Status | Available |
| PDF Link | https://www.nsjbio.com/tds-pdf/recombinant-cd43-antibody-spn6562r-v9537 |
| Title | Recombinant CD43 Antibody |
| Description | It recognizes a cell surface glycoprotein of 95/115/135kDa (depending upon the extent of glycosylation), identified as CD43. 70-90% of T-cell lymphomas and from 22-37% of B-cell lymphomas express CD43. No reactivity has been observed with reactive B-cells. So a B-lineage population that co-expresses CD43 is highly likely to be a malignant lymphoma, especially a low-grade lymphoma, rather than a reactive B-cell population. When CD43 antibody is used in combination with anti-CD20, effective immunophenotyping of the lymphomas in formalin-fixed tissues can be obtained. Co-staining of a lymphoid infiltrate with anti-CD20 and anti-CD43 argues against a reactive process and favors a diagnosis of lymphoma. |
Share
